Andrew Awad

Pymaceuticals

Capomulin is the only drug that seems to be effecting any change on the tumor volume. All the other drug saw the tumor volume increase over the 45 days of the trial, while only Capomulin was able to decrease the size of the tumor by 19% . The survival rate of the mice also show that Capomulin had the best effects with a 84% survival rate after 45 days which is almost double the next best treatments.

Infubinol and Ketapril were on par with the placebo treatment for the most part. Infubinol did a little better than the placebo with tumor volume and metastatic sites spread, however had a lower survival rate than the placebo. On the other hand, Ketapril did worse than the placebo in every measure except the survival rate, where it had the same rate as the placebo after 45 days. However, the survival rate of Ketapril takes a sharp down turn after 40 days which may indicate that if trial was for a little longer, Ketapril would have most likely dropped lower than the placebo.

In Conclusion, Capomulin is the only treatment that should be given to decrease a tumor’s volume and limit the Metastatic sites spread. Infubinol and Ketapril can not be considered as a treatment to tumors from these studies, in fact, they should be avoided since they seem to have a worse or similar effect as the placebo.